Vyvanse Bed denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvanse bed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Step Therapy for Vyvanse in BED

Blue Cross Blue Shield step-therapy (also called "fail-first") protocols require you to try one or more lower-cost medications or behavioral treatments before the plan will authorize a preferred or brand-name agent. For Vyvanse in binge eating disorder, the plan may require documentation of prior attempts at behavioral interventions — such as structured psychotherapy — or, in some plan variants, trials of other pharmacologic options it considers first-line. The denial does not necessarily mean Vyvanse is inappropriate; it means the plan needs evidence that you have already taken the required steps.

## Why This Denial Is Appealable

Step-therapy requirements are subject to several important limitations. Many states have passed step-therapy reform laws that require insurers to grant exceptions when: the required first-step treatment is contraindicated or clinically inappropriate; the patient already tried and failed the required therapy; or the required step would cause foreseeable harm. At the federal level, ACA external reviewers evaluate whether a plan's step-therapy protocol is being applied in a clinically reasonable manner. Because Vyvanse is the only FDA-approved medication for moderate-to-severe BED, the step-therapy premise deserves close scrutiny — there may be no FDA-approved pharmacologic step for the plan to require.

## Federal Appeal Framework

• Step-therapy exception request — many BCBS plans have a specific step-therapy override form; submit this as your first action.
• Internal appeal — file within the deadline on your denial notice (commonly 180 days).
• State law protections — check whether your state has a step-therapy reform statute; if so, cite it in your appeal.
• External review (ACA §2719) — after a final internal denial on a fully-insured plan, you have approximately four months to request independent review. External reviewers may apply state step-therapy standards.
• ERISA §503 — self-funded employer plans must provide a full-and-fair review; state step-therapy laws may not apply, but federal parity and reasonableness standards do.
• Expedited track — available when the standard timeline would seriously jeopardize health.

## Documentation to Gather

1. BED diagnosis records — DSM-5 documentation of moderate-to-severe BED, with severity and functional-impairment details. 2. Step-therapy history — for every treatment the plan's protocol requires, document the agent or therapy type, the duration of the trial, the outcome, and the reason for discontinuation or inadequate response. 3. Prior-treatment contraindication or inappropriateness statement — if any required step is clinically inappropriate for this patient, your prescriber should explain why in writing. 4. Prescriber medical-necessity letter — addressing the step-therapy criteria specifically and explaining why Vyvanse is the appropriate next step. 5. FDA prescribing label — confirming the labeled BED indication and the clinical profile of the drug.

## Criteria-Mapping Structure

Obtain the BCBS step-therapy protocol for Vyvanse in BED. List each required step. For each step: document either that it was completed (with dates and outcomes) or that it is clinically inappropriate (with the prescriber's stated reason). A complete step history — even one that shows all steps were already taken — turns a denial into an approval in many cases. If no suitable pharmacologic step exists, state that explicitly and cite the FDA label to support the absence of a therapeutic equivalent.